Dr. Barry Dworkin

Danish studies find higher risk of optic nerve damage with Ozempic however absolute risk increase is 1 in 10,000 and biological mechanism to explain this remains elusive.

Medical Mythbusting Commentary for January 17, 2025

Source:
Danish studies find higher risk of optic nerve damage with Ozempic

Reference:
Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes

Related posts:

  1. Popular weight loss and diabetes drugs linked to increased risk of rare form of blindness. Study authors state that causality is not established. The health benefits of controlling diabetes, reduced heart, liver, kidney, and brain disease need to be considered with its use.
  2. Diabetes drug in short supply in U.S. (but not in Canada) after celebrities, influencers touted its weight-loss benefits.
  3. Ozempic and similar drugs linked to gastrointestinal conditions: B.C. researchers. Already known but needs context about rarity of some of the side effects versus the beneficial health outcomes when assessing overall risk of its use.
  4. Government digging into Tamiflu stockpile to combat flu; unfortunately evidence that the drug works as purported by drug company is being questioned